The first-in-human phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors.
Fu S, Shen L, Lu S, Sommerhalder D, Liu T, Spira A, Li J, Yu Y, Li W, Li J, Song B, Dong C, Lai L, Ma S, Shang E, Zhong B, Zhang T. The first-in-human phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors. Journal Of Clinical Oncology 2025, 43: 3083-3083. DOI: 10.1200/jco.2025.43.16_suppl.3083.Peer-Reviewed Original ResearchMaximum tolerated doseNon-small cell lung cancer modelTreatment related adverse eventsPancreatic ductal carcinomaColorectal cancerSolid tumorsFirst-in-human phase 1/2 studyRecommended phase 2 doseTumor cells in vitroMedian prior linesPhase 1/2 studyPhase 1b/2 studyPhase 2 dosePhase 2 partRelated grade 3Dose-limiting toxicityAdvanced solid tumorsDose-escalation partEvaluated dose rangeNausea and diarrheaInhibited tumor growthLung cancer modelRelated adverse eventsStandard of careCells in vitro
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply